1/26 Dr. Pestell patent:
Ccr5 determing likely risk for developing cancer metastasis
___
Using modulators of CCR5 for treating cancer
In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining 5 CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
0072]..." CCR5 is mainly expressed in memory T-cells, macrophages, and immature dendritic cells, and is upregulated by 10 proinflammatory cytokines."
___
0074] Prior to the present disclosure, the roles of the chemokine CCL5 and its receptor CCR5 in cancer progression were unclear.
https://patents.google.com/patent/AU202220199...G.+Pestell
___
*Cytodyn = CCR5 Receptors
*Dr. Pestell = CCR5 / Metastatic risk
*Creativ = Liquid Biopsy sequence / ICI dosing
__
Dr. Pestll patent open up the group to patients for re-testing who are told they are cancer stable ?
Reads to me as a yes
Combine the 3 patent holders & a outstanding Targeted Immunotherapy pharmaceutical industry is being designed:
The future of medicine
Ccr5 determing likely risk for developing cancer metastasis
___
Using modulators of CCR5 for treating cancer
In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining 5 CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
0072]..." CCR5 is mainly expressed in memory T-cells, macrophages, and immature dendritic cells, and is upregulated by 10 proinflammatory cytokines."
___
0074] Prior to the present disclosure, the roles of the chemokine CCL5 and its receptor CCR5 in cancer progression were unclear.
https://patents.google.com/patent/AU202220199...G.+Pestell
___
*Cytodyn = CCR5 Receptors
*Dr. Pestell = CCR5 / Metastatic risk
*Creativ = Liquid Biopsy sequence / ICI dosing
__
Dr. Pestll patent open up the group to patients for re-testing who are told they are cancer stable ?
Reads to me as a yes
Combine the 3 patent holders & a outstanding Targeted Immunotherapy pharmaceutical industry is being designed:
The future of medicine
5
